MRNA : 2-month performance

IPOs this week : Feb. 11 - 15, 2019

IPOs expected to price:

• Anchiano Therapeutics (ANCN) on February 11; 
• Virgin Trains USA (VTUS) on February 12; 
• TCR2 Therapeutics (TCRR), 
• Cibus (CBUS) and Avedro (AVDR) on February 13; 
• Stealth BioTherapeutics (MITO) on February 14.

IPO activity: In case you missed it, the IPO market was lit up with the news that Postmates (POSTM) and Slack (SLACK) filed for confidential listings.

There are IPO share lock-up expirations upcoming on Avalon GloboCare (OTCQB:AVCO) and Aridis Pharmaceuticals (NASDAQ:ARDS) on February 12 and Safe-T (NASDAQ:SFET) on February 13.

Gossamer Bio (GOSS) began trading on the Nasdaq on 8 February 2019

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

Sector: Healthcare

• Industry: Biotechnology
• Full Time Employees: 144
• Founded by Faheem Hasnain and Sheila Gujrathi in 2015
• Headquartered in San Diego, California
• https://www.gossamerbio.com

Ticker: GOSS

Gossamer Bio opened for trading at $19 after pricing upsized 17.25 mln share IPO (from 14.375 mln shares) IPO at $16, in-line with expected range